OTCMKTS:ZLDPF Zealand Pharma A/S (ZLDPF) Stock Price, News & Analysis $41.99 -1.12 (-2.59%) As of 09/24/2026 01:15 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsNews and TrendsSEC FilingsShort Interest About Zealand Pharma A/S Stock (OTCMKTS:ZLDPF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Zealand Pharma A/S alerts:Sign Up Key Stats Today's Range$41.99▼$41.9950-Day Range$41.99▼$52.6852-Week Range$35.93▼$83.12Volume100 shsAverage Volume718 shsMarket Capitalization$3.00 billionP/E Ratio6.96Dividend YieldN/APrice TargetN/AConsensus RatingHold Company Overview Zealand Pharma A/S is a Denmark-based biotechnology company focused on discovering, developing and commercializing peptide-based medicines. The company’s research programs address serious and underserved conditions, particularly metabolic diseases, gastrointestinal disorders and rare diseases. Zealand combines proprietary peptide technologies with drug-development expertise to create therapies designed to improve treatment outcomes and patient convenience. Zealand’s commercial portfolio includes Zegalogue (dasiglucagon), an injectable treatment for severe hypoglycemia in people with diabetes. The company is also advancing a pipeline of investigational medicines, including treatments for obesity, metabolic dysfunction and other chronic conditions. Several programs are being developed through collaborations with international pharmaceutical companies, including a partnership with Boehringer Ingelheim for survodutide, an investigational medicine being studied in metabolic disease. Founded in 1998, Zealand Pharma is headquartered in Søborg, Denmark, and serves international markets through its own commercial activities and strategic partnerships. The company’s leadership is headed by Chief Executive Officer Adam Steensberg, who has overseen the organization’s focus on late-stage development, commercialization and partnerships in metabolic and rare-disease medicine.AI Generated. May Contain Errors. Read More Zealand Pharma A/S Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks31st Percentile Overall ScoreZLDPF MarketRank™: Zealand Pharma A/S scored higher than 31% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.9 / 5Analyst RatingHold Consensus RatingZealand Pharma A/S has received a consensus rating of Hold. The company's average rating score is 2.27, and is based on 1 strong buy rating, 1 buy rating, 9 hold ratings, and no sell ratings.Amount of Analyst CoverageZealand Pharma A/S has only been the subject of 4 research reports in the past 90 days.Read more about Zealand Pharma A/S's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth-30.14% Earnings GrowthEarnings for Zealand Pharma A/S are expected to decrease by -30.14% in the coming year, from $3.65 to $2.55 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Zealand Pharma A/S is 6.96, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.93.Price to Earnings Ratio vs. SectorThe P/E ratio of Zealand Pharma A/S is 6.96, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.39.Price to Book Value per Share RatioZealand Pharma A/S has a P/B Ratio of 1.33. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Zealand Pharma A/S's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted0.85% of the float of Zealand Pharma A/S has been sold short.Short Interest Ratio / Days to CoverZealand Pharma A/S has a short interest ratio ("days to cover") of 238.47, which indicates bearish sentiment.Change versus previous monthShort interest in Zealand Pharma A/S has recently increased by 8.55%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldZealand Pharma A/S does not currently pay a dividend.Dividend GrowthZealand Pharma A/S does not have a long track record of dividend growth. News and Social Media3.1 / 5News Sentiment1.00 News SentimentZealand Pharma A/S has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Zealand Pharma A/S this week, compared to 1 article on an average week. Company OwnershipN/AInsider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Zealand Pharma A/S insiders have not sold or bought any company stock.Percentage Held by InstitutionsZealand Pharma A/S has minimal institutional ownership at this time.Read more about Zealand Pharma A/S's insider trading history. Receive ZLDPF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zealand Pharma A/S and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ZLDPF Stock News HeadlinesZealand Pharma A/S (OTCMKTS:ZLDPF) Stock Rated "Hold" by Wall Street Brokerages1 hour ago | americanbankingnews.comZealand Pharma's short bowel syndrome drug wins backing from EU panelSeptember 18, 2026 | reuters.comSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor. This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely. | Altimetry (Ad)Zealand Pharma: A Play On Medicine Discovery, But Too Expensive Right NowSeptember 9, 2026 | seekingalpha.comZealand Pharma - Transactions related to share buy-back program (week 34, 2026)August 24, 2026 | markets.businessinsider.comZealand Pharma â Notification of holding of treasury sharesAugust 24, 2026 | markets.businessinsider.comZealand Pharma A/SAugust 20, 2026 | barrons.comZealand Pharma - Transactions related to share buy-back program (week 33, 2026)August 17, 2026 | markets.businessinsider.comSee More Headlines ZLDPF Stock Analysis - Frequently Asked Questions How have ZLDPF shares performed this year? Zealand Pharma A/S's stock was trading at $72.8675 on January 1st, 2026. Since then, ZLDPF shares have decreased by 42.4% and is now trading at $41.99. How were Zealand Pharma A/S's earnings last quarter? Zealand Pharma A/S (OTCMKTS:ZLDPF) released its quarterly earnings data on Thursday, May, 7th. The company reported ($0.87) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.37) by $0.50. The company earned $5.33 million during the quarter, compared to analyst estimates of $2.81 million. Zealand Pharma A/S had a trailing twelve-month return on equity of 18.53% and a net margin of 58.86%. How do I buy shares of Zealand Pharma A/S? Shares of ZLDPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/07/2026Today9/25/2026Next Earnings (Estimated)11/12/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolOTCMKTS:ZLDPF Previous SymbolNASDAQ:ZLDPF CIK2068427 Webwww.zealandpharma.com Phone45-8877-3600Fax45-8877-3898Employees340Year Founded1998Profitability EPS (Trailing Twelve Months)$6.03 Trailing P/E Ratio6.96 Forward P/E Ratio11.50 P/E GrowthN/ANet Income$977.29 million Net Margins58.86% Pretax Margin74.39% Return on Equity18.53% Return on Assets17.14% Debt Debt-to-Equity Ratio0.02 Current Ratio37.17 Quick Ratio37.17 Sales & Book Value Annual Sales$1.40 billion Price / Sales2.15 Cash Flow$13.46 per share Price / Cash Flow3.12 Book Value$31.61 per share Price / Book1.33Miscellaneous Outstanding Shares71,530,000Free FloatN/AMarket Cap$3.00 billion OptionableNot Optionable Beta0.89 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (OTCMKTS:ZLDPF) was last updated on 9/25/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zealand Pharma A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Zealand Pharma A/S With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
